However, compared with the control group, the expression of caspase-3 in the PCOS-HFD group was significantly upregulated (P < 0.05), while after BBR administration, its expression was downregulated in the PCOS-HFD + BBR group (P < 0.05, Fig. 6a, g). The gene discussed is CASP3; the disease is polycystic ovary syndrome.